Viewing Study NCT05903833

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2026-01-31 @ 7:06 AM
Study NCT ID: NCT05903833
Status: RECRUITING
Last Update Posted: 2025-09-09
First Post: 2023-05-11
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Sponsor: AGO Research GmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Vulvar Cancer View
None Persistent Vulvar Cancer View
None Metastatic Vulva Cancer View
None Locally Advanced Vulvar Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced vulvar cancer View
None Recurrent vulvar cancer View
None Persistent vulvar canser View
None Metastatic vulvar cancer View
None Locally advanced vulvar cancer View
None Pembrolizumab View
None Lenvatinib View